Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by Focus Partners Wealth

Focus Partners Wealth lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,955 shares of the medical equipment provider’s stock after purchasing an additional 427 shares during the quarter. Focus Partners Wealth’s holdings in Zimmer Biomet were worth $1,919,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in ZBH. Ameriprise Financial Inc. raised its position in shares of Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after purchasing an additional 3,208,596 shares during the period. JPMorgan Chase & Co. grew its holdings in Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after buying an additional 1,488,918 shares in the last quarter. Nuveen LLC bought a new position in Zimmer Biomet in the 1st quarter worth approximately $155,891,000. Alyeska Investment Group L.P. bought a new position in Zimmer Biomet in the 1st quarter worth approximately $101,294,000. Finally, Boston Trust Walden Corp bought a new position in Zimmer Biomet in the 1st quarter worth approximately $54,108,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZBH. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Evercore ISI decreased their price objective on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating for the company in a report on Tuesday, July 8th. UBS Group increased their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a report on Friday, August 8th. Raymond James Financial increased their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Finally, Royal Bank Of Canada increased their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $111.00.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.70% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $99.09 on Wednesday. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72. The stock has a fifty day moving average of $99.74 and a 200-day moving average of $99.49. The company has a market capitalization of $19.63 billion, a PE ratio of 24.11, a price-to-earnings-growth ratio of 2.32 and a beta of 0.68. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the prior year, the firm earned $2.01 EPS. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.